Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term safety of intravenous and subcutaneous efgartigimod in children with generalized myasthenia gravis (ADAPT Jr+)
2023-507379-23-00Phase 3Authorised
- Sponsor
- argenx
- Start
- Aug 2022
- Modality
- Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 15
01
Overview
Phase 3, open-label, single-arm trial of efgartigimod alfa in myasthenia gravis (MG), sponsored by argenx. Primary endpoints: Incidence and severity of adverse events, Incidence and severity of serious adverse events and 2 more. Planned start Aug 2022; status: authorised.
02
Drugs
efgartigimod alfa
03
Conditions
myasthenia gravis (MG)
Beyond the preview
Go deeper on 2023-507379-23-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-507379-23-00.